The University of Southampton
University of Southampton Institutional Repository

Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease

Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease
Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease
Objective FibroTouch is a newly developed device to assess ultrasound attenuation parameter (UAP) and liver stiffness measurement to quantify hepatic steatosis and fibrosis, respectively. However, there is currently a lack of defined thresholds of UAP to diagnose different stages of hepatic steatosis. We aimed to assess the optimal thresholds of UAP for hepatic steatosis in individuals with biopsy-proven fatty liver disease (FLD).
Methods We enrolled 497 adults with FLD undergoing FibroTouch and liver biopsy. Area under the receiver operating characteristic curve (AUROC) was performed to calculate the performance of UAP in staging hepatic steatosis. Hepatic steatosis >33% was defined as significant steatosis. We determined the optimal cutoff values of UAP and the sensitivity or specificity higher than 90%. Sensitivity, specificity, positive predictive value and negative predictive value were subsequently calculated.
Results The median UAP for the enrolled patients was 308 dB/m. Multivariable logistic regression analysis showed that UAP was associated with significant steatosis [adjusted-odds ratio 1.05, 95% confidence interval (CI), 1.02–1.09; P = 0.001]. The AUROCs for S ≥ 1, S ≥ 2 and S = 3 were 0.88 (95% CI, 0.84–0.91), 0.77 (95% CI, 0.73–0.81), and 0.70 (95% CI, 0.63–0.77), respectively. The optimal UAP cutoffs were 295 dB/m for S ≥ 1, 314 dB/m for S ≥ 2, and 324 dB/m for S = 3. Almost identical results were observed in the subgroup of patients with biopsy-confirmed nonalcoholic fatty liver disease (n = 435).
Conclusion We found that the AUROC values of UAP by FibroTouch were ranging from 0.70 to 0.88 for assessing hepatic steatosis severity. These UAP cutoffs could be applicable for clinical use.
0954-691X
430-435
Zhu, Sheng-Hao
99f2b08c-4c7b-4530-90ec-a0b797d95b10
Zheng, Kenneth I.
fa648912-c163-496f-b6c3-fa1a1176a206
Hu, Di-Shuang
f97232d4-da35-4f52-8865-2b2f4dc274a1
Gao, Feng
b70fc7ee-1c00-4b32-aa1a-272e603a3add
Rios, Rafael S.
0adc694c-90e3-49f5-a94b-53e30c0f6171
Li, Gang
6dba62d2-c871-4596-9491-5035f263a85e
Li, Yang-Yang
d04d60c4-cc46-4646-bf5c-691561d75826
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Targher, Giovanni
043e0811-b389-4922-974e-22e650212c5f
Chen, Yong-Ping
70927630-d1a1-4968-adb8-56dee8cf1dd1
Zheng, Ming-Hua
3692655b-7a8c-46d8-aaa7-48807dbb54ae
Zhu, Sheng-Hao
99f2b08c-4c7b-4530-90ec-a0b797d95b10
Zheng, Kenneth I.
fa648912-c163-496f-b6c3-fa1a1176a206
Hu, Di-Shuang
f97232d4-da35-4f52-8865-2b2f4dc274a1
Gao, Feng
b70fc7ee-1c00-4b32-aa1a-272e603a3add
Rios, Rafael S.
0adc694c-90e3-49f5-a94b-53e30c0f6171
Li, Gang
6dba62d2-c871-4596-9491-5035f263a85e
Li, Yang-Yang
d04d60c4-cc46-4646-bf5c-691561d75826
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Targher, Giovanni
043e0811-b389-4922-974e-22e650212c5f
Chen, Yong-Ping
70927630-d1a1-4968-adb8-56dee8cf1dd1
Zheng, Ming-Hua
3692655b-7a8c-46d8-aaa7-48807dbb54ae

Zhu, Sheng-Hao, Zheng, Kenneth I., Hu, Di-Shuang, Gao, Feng, Rios, Rafael S., Li, Gang, Li, Yang-Yang, Byrne, Christopher, Targher, Giovanni, Chen, Yong-Ping and Zheng, Ming-Hua (2021) Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease. European Journal of Gastroenterology & Hepatology, 33 (3), 430-435. (doi:10.1097/MEG.0000000000001746).

Record type: Article

Abstract

Objective FibroTouch is a newly developed device to assess ultrasound attenuation parameter (UAP) and liver stiffness measurement to quantify hepatic steatosis and fibrosis, respectively. However, there is currently a lack of defined thresholds of UAP to diagnose different stages of hepatic steatosis. We aimed to assess the optimal thresholds of UAP for hepatic steatosis in individuals with biopsy-proven fatty liver disease (FLD).
Methods We enrolled 497 adults with FLD undergoing FibroTouch and liver biopsy. Area under the receiver operating characteristic curve (AUROC) was performed to calculate the performance of UAP in staging hepatic steatosis. Hepatic steatosis >33% was defined as significant steatosis. We determined the optimal cutoff values of UAP and the sensitivity or specificity higher than 90%. Sensitivity, specificity, positive predictive value and negative predictive value were subsequently calculated.
Results The median UAP for the enrolled patients was 308 dB/m. Multivariable logistic regression analysis showed that UAP was associated with significant steatosis [adjusted-odds ratio 1.05, 95% confidence interval (CI), 1.02–1.09; P = 0.001]. The AUROCs for S ≥ 1, S ≥ 2 and S = 3 were 0.88 (95% CI, 0.84–0.91), 0.77 (95% CI, 0.73–0.81), and 0.70 (95% CI, 0.63–0.77), respectively. The optimal UAP cutoffs were 295 dB/m for S ≥ 1, 314 dB/m for S ≥ 2, and 324 dB/m for S = 3. Almost identical results were observed in the subgroup of patients with biopsy-confirmed nonalcoholic fatty liver disease (n = 435).
Conclusion We found that the AUROC values of UAP by FibroTouch were ranging from 0.70 to 0.88 for assessing hepatic steatosis severity. These UAP cutoffs could be applicable for clinical use.

Text
draft - Accepted Manuscript
Download (79kB)
Text
Table 1 - Accepted Manuscript
Download (20kB)
Text
Table 2 - Accepted Manuscript
Download (17kB)
Text
Table 3 - Accepted Manuscript
Download (20kB)
Image
Figure 1 - Accepted Manuscript
Download (94kB)
Image
Figure 2 - Accepted Manuscript
Download (2MB)

Show all 6 downloads.

More information

Accepted/In Press date: 2 April 2020
e-pub ahead of print date: 8 May 2020
Published date: 1 March 2021
Additional Information: Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Identifiers

Local EPrints ID: 439479
URI: http://eprints.soton.ac.uk/id/eprint/439479
ISSN: 0954-691X
PURE UUID: a7156273-207c-43a2-b2de-9575db8937b7
ORCID for Christopher Byrne: ORCID iD orcid.org/0000-0001-6322-7753

Catalogue record

Date deposited: 24 Apr 2020 16:30
Last modified: 17 Mar 2024 05:28

Export record

Altmetrics

Contributors

Author: Sheng-Hao Zhu
Author: Kenneth I. Zheng
Author: Di-Shuang Hu
Author: Feng Gao
Author: Rafael S. Rios
Author: Gang Li
Author: Yang-Yang Li
Author: Giovanni Targher
Author: Yong-Ping Chen
Author: Ming-Hua Zheng

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×